Please login to the form below

Not currently logged in

The Access Partnership hires Mike Mallinson

He joins with more than 30 years’ experience gained both on agency and client-side

London-based The Access Partnership, part of the The Research Partnership, has appointed Mike Mallinson as president of the market access consultancy firm.

Mallinson has more than 30 years' experience, gained both on agency and client-side. Most recently he served as UK MD for market access, and pricing and reimbursement specialists, Double Helix Consulting, while prior to this he established a payer, pricing, reimbursement and market access practice within GfK's healthcare division.

In his new role, Mallison will be supported by Rob White, global director of market access and Dr Shrinivas Rao Mukku, global director of pricing and reimbursement.

“I am delighted to be taking on this challenging new position,” said Mallinson.

“Our aim is for The Access Partnership to become the preferred commercial partner for delivering market access solutions, by gaining a reputation for delivering the best payer and key stakeholder insights and outstanding strategic consulting services.

“We recognise the access challenges facing our clients, particularly across the Tier I and Tier II emerging markets - having an Asia Pacific presence will mean we are well placed to meet our clients' needs in this region.”

2nd November 2012

From: Marketing, Healthcare



Featured jobs

Subscribe to our email news alerts


Add my company

Our higher purpose is to deliver better communication to increase and speed up the ability of patients to access better...

Latest intelligence

How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...
figure 1
The valuable brand
Creating value beyond the pill is both possible and increasingly necessary...